MRVI · Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences delivered a strong Q1 2026 performance with total revenue of $65.8 million, up 40.5% year-over-year, primarily propelled by TriLink segment growth to $47.5 million (+65.1%), including $14.3 million from high-volume CleanCap orders for commercial COVID-19 vaccines. Excluding this COVID-related revenue, TriLink base revenue still expanded 15.4%, reflecting robust demand in Discovery and GMP consumables. Cygnus contributed $18.4 million, up 1.4%, supported by North America and EMEA demand despite distributor timing issues in China. Gross profit surged to $33.7 million from $7.7 million, driven by revenue growth and improved cost structure, though operating expenses remained elevated at $35.9 million including $2.9 million in restructuring costs. This resulted in a narrower GAAP net loss of $(6.4) million versus $(52.9) million last year, with Adjusted EBITDA flipping to a positive $20.3 million from $(10.5) million, highlighting operational efficiency gains. CEO Bernd Brust emphasized improving core TriLink base business demand and higher-margin portfolio strength, crediting disciplined cost management for EBITDA expansion and the return to positive free cash flow of $4.2 million. The company raised full-year 2026 guidance to $205-215 million in revenue (from $200-210 million) and $30-32 million in Adjusted EBITDA (from $18-20 million), signaling confidence in sustained growth amid better visibility. TriLink's total revenue growth of 65% underscores recovery in vaccine-related demand, while base business momentum and cash flow positivity indicate structural improvements positioning Maravai for long-term profitability.